SGLT2 inhibitors – the science behind organ benefits

AstraZeneca |

Chair: Jiten Vora (UK)
Co-chair: Nayyar Iqbal (USA)

13:00 – 13:05Welcome and introductionsJiten Vora (UK)
Nayyar Iqbal (USA)
Elisabeth Björk (SWE)
13:05 – 13:15Do metabolic changes explain organ benefits?Jiten Vora (UK)
13:15 – 13:45Are mechanisms of SGLT2 inhibition the same across the EF spectrum?Lars Lund (SWE)
13:45 – 14:05The science underlying renal benefitsVolker Vallon (USA)
14:05 – 14:25Panel discussion

Jiten Vora (UK)
Lars Lund (SWE)
Volker Vallon (USA)

14:25 – 14:30Closing remarksJiten Vora (UK)
Regina Fritsche-Danielson (SWE)